Blog
    Peptide SpotlightFor PhysiciansJuly 23, 2026

    Testosterone Cypionate and Enanthate Clinical Evidence

    Review clinical data on testosterone esters for hypogonadism, including TRAVERSE trial findings on cardiovascular safety, bone density, and sexual function.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    In men with confirmed hypogonadism, what are the documented clinical outcomes of intramuscular (IM) testosterone esters regarding sexual function, bone density, and cardiovascular safety?

    Evidence Snapshot

    • Therapeutic Class: Long-acting intramuscular (IM) testosterone esters (Grade: A).
    • Dosing Protocols: 50–400 mg IM administered every 2–4 weeks (clinical practice frequently utilizes weekly split-dosing).
    • Primary Study Populations: Confirmed hypogonadal men, including those aged 65 years and older (TTrials) and larger cohorts (TRAVERSE; n=5,246).
    • Key Outcomes: Improvements in sexual activity, hemoglobin levels, and volumetric bone mineral density (BMD).
    • Safety Status: FDA-approved; cardiovascular noninferiority established in the TRAVERSE trial.

    What the Research Shows

    The clinical evidence for Testosterone Cypionate and Enanthate (IM) is characterized by robust data in specific physiological domains. According to the TTrials, which focused on hypogonadal men aged 65 and older, testosterone replacement therapy (TRT) resulted in modest improvements in sexual activity and hemoglobin levels. Furthermore, research indicate that these esters provide the strongest evidence among TRT options for the correction of anemia and improvements in sexual function in patients with confirmed hypogonadism.

    Cardiovascular safety has been a primary focus of large-scale research. The TRAVERSE trial (n=5,246) demonstrated that testosterone therapy was noninferior to placebo regarding cardiovascular outcomes. This finding led to the removal of boxed cardiovascular (CV) warnings. However, the FDA has implemented class-wide blood pressure (BP) warnings for these agents.

    Regarding skeletal health, the evidence is nuanced. While data from the TTrials indicates that testosterone administration improves volumetric bone mineral density (BMD), larger-scale data from the TRAVERSE trial did not demonstrate a fracture benefit despite these imaging-based improvements.

    Mechanism

    The mechanism of Testosterone Cypionate and Enanthate involves the hydrolysis of the ester group upon administration, which releases testosterone into the systemic circulation. Once released, the therapy operates through exogenous androgen receptor agonism. This action results in the suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via the hypothalamic-pituitary-gonadal axis, subsequently suppressing intratesticular testosterone production.

    Limitations of the Evidence

    Significant gaps remain in the clinical understanding of testosterone esters. Although volumetric bone density (BMD) improves with therapy, the TRAVERSE trial failed to show a definitive reduction in fractures, suggesting a potential dissociation between imaging changes and clinical outcomes.

    Furthermore, the evidence for non-physical endpoints appears weaker than for physiological changes. Data regarding cognitive function and vitality endpoints are less robust than the data collected for imaging changes (such as BMD) or laboratory markers (such as hemoglobin). While cardiovascular noninferiority was established in TRAVERSE, the long-term implications of the FDA-mandated class-wide blood pressure warnings require careful consideration in clinical monitoring.

    Clinical Takeaway

    Testosterone Cypionate and Enanthate (IM) are FDA-approved agents with Grade A evidence for treating confirmed hypogonadism. Research confirms their efficacy in improving sexual activity, anemia, and bone density markers, with established cardiovascular noninferiority in large cohorts. However, these physiological improvements do not currently correlate with a reduction in fracture risk, and clinicians must account for class-wide warnings regarding blood pressure elevation.

    Sources

    • TruthTides Clinical Database: Testosterone Cypionate/Enanthate (IM)
    • TRAVERSE Trial (n=5,246)
    • TTrials (Hypogonadal men ≥65 years)
    • FDA Regulatory Records

    Referenced Peptides

    testosterone cypionatetestosterone enanthate

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.